<article>
<section>
<h1 id="header">Protocol for sleep analysis in the brain of genetically modified adult mice</h1>
<p><time datetime="2021-12-10">Published: December 10, 2021</time></p>
<p>Kanako Iwasaki,<sup><a href="#aff1">1</a>,<a href="#fn1">5</a>,<a href="#cor1">*</a></sup> Noriko Hotta-Hirashima,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a></sup> Hiromasa Funato,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#cor2">**</a></sup> and Masashi Yanagisawa<sup><a href="#aff1">1</a>,<a href="#aff3">3</a>,<a href="#aff4">4</a>,<a href="#fn2">6</a>,<a href="#cor3">***</a></sup></p>
<p id="aff1"><sup>1</sup>International Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan</p>
<p id="aff2"><sup>2</sup>Department of Anatomy, Graduate School of Medicine, Toho University, Ota-ku, Tokyo 951-8585, Japan</p>
<p id="aff3"><sup>3</sup>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA</p>
<p id="aff4"><sup>4</sup>Life Science Center, Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan</p>
<p id="fn1"><sup>5</sup>Technical contact</p>
<p id="fn2"><sup>6</sup>Lead contact</p>
<p id="cor1"><sup>*</sup>Correspondence: <a href="mailto:kinapowder.1993@gmail.com">kinapowder.1993@gmail.com</a></p>
<p id="cor2"><sup>**</sup>Correspondence: <a href="mailto:funato.hiromasa.km@u.tsukuba.ac.jp">funato.hiromasa.km@u.tsukuba.ac.jp</a></p>
<p id="cor3"><sup>***</sup>Correspondence: <a href="mailto:yanagisawa.masa.fu@u.tsukuba.ac.jp">yanagisawa.masa.fu@u.tsukuba.ac.jp</a></p>
<p><span class="open-access">Open Access</span> • DOI: <a href="https://doi.org/10.1016/j.xpro.2021.100982">10.1016/j.xpro.2021.100982</a></p>
</section>
<section>
<h2 id="summary">Summary</h2>
<p>Elucidating the molecular pathways that regulate animal behavior such as sleep is essential for understanding how the brain works. However, to examine how a certain functional domain of protein is involved in animal behavior is challenging. Here, we present a protocol for inducing endogenous protein that lacks a specific functional domain using Cre-mediated allele modification in neurons followed by electroencephalogram/electromyogram (EEG/EMG) recording to study the role of kinases in sleep. This strategy is applicable to other gene targets or behaviors.</p>
<p>For complete details on the use and execution of this protocol, please refer to <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref6">Iwasaki et al. (2021)</a>.</p>




<div class="highlights">
<h3>Highlights</h3>
<ul>
<li>Temporal- and cell type-specific allele induction to regulate protein function</li>
<li>Intraperitoneal administration of tamoxifen induces Cre-dependent allele induction</li>
<li>An electrode implant and tether cable acquire EEG/EMG signals of a freely moving mouse</li>
<li>Allele-specific antibodies show tamoxifen-dependent recombination</li>
</ul>
</div>
<div class="graphical-abstract">
<h3>Graphical abstract</h3>
<figure><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-GA.jpg" alt="GraphicalAbstract.jpg"></figure>
</div></section>
<section>
<h2 id="before-you-begin">Before you begin</h2>
<div class="note">
<span class="note-title">Note:</span> All animal work presented here was approved (Protocol#180094) and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of Tsukuba.</div>
<p>Here, we describe materials and methods for the induction of SIK3 lacking a protein kinase A (PKA)-phosphorylation site in neurons using <i>Sik3</i><sup><i>ex13flox</i></sup> and <i>synapsin1</i><sup><i>CreERT2</i></sup> mice (<a href="#bib3">Funato et al., 2016</a>; <a href="#bib4">Honda et al., 2018</a>; <a href="#bib6">Iwasaki et al., 2021</a>). Intraperitoneal injection of tamoxifen in late infancy leads to the expected recombination and increases non-rapid eye movement sleep (NREM sleep) in <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox</i></sup> mice. Using other flox mice, the researchers are able to induce or delete the target domain or the entire protein in adult brains. To confirm the successful allele induction, it is desirable to obtain or create a variety of antibodies that detect allele-specific and/or general form of the target protein. When there are no available antibodies, RT-PCR can be used to confirm allele induction. To visualize Cre-mediated recombination induced by tamoxifen, crosses with reporter mouse lines such as <i>ROSA26</i><sup><i>LacZ</i></sup> mouse are useful to observe detailed spatial recombination.</p>
<h3 id="sec1.1">Tamoxifen dosage</h3>
<p>In general, higher doses of tamoxifen administration guarantee higher recombination rates, but at the same time lower survival rates (<a href="#tbl1">Table 1</a>). Donocoff and colleagues showed that almost all C57BL/6 mouse given five daily 6 mg tamoxifen (equivalent to 200 mg/kg body weight (BW) in a 30 g mouse) were dead in 2 weeks whereas 70% of those given 3 mg tamoxifen survived (<a href="#bib2">Donocoff et al., 2020</a>). According to Valny and colleagues, peak concentrations of tamoxifen metabolite 4-hydroxytamoxifen in adult brains, which presumably be a major CreERT2 inducer, were unchanged between 2 daily 200 mg/kg BW and 100 mg/kg BW administration, but faster degradation was seen at the lower dose (<a href="#bib12">Valny et al., 2016</a>). After five daily intraperitoneal injection of 100 mg/kg BW tamoxifen from P28 to sodium-dependent L-glutamate/L-aspartate transporter (GLAST)-CreERT2 mice results in nearly 100% recombination in the cerebral cortex (<a href="#bib7">Jahn et al., 2018</a>). Five times 100 mg/kg BW tamoxifen injection were performed every alternative day for 10 days from 3 weeks old, which provided high efficient recombination (<a href="#bib5">Huang et al., 2018</a>). These reports suggest that repeated injections of 100 mg/kg BW tamoxifen are reasonable to achieve high recombination efficiency while maintaining low lethality.</p>
<table id="tbl1" class="dense-table">
<caption>Table 1. Literature using tamoxifen administration targeting the central nervous system</caption>
<thead>
<tr>
<th colspan="7">Tamoxifen administration to neonatal-adolescent mice</th>
</tr>
<tr>
<th>References</th>
<th>PMID</th>
<th>Route</th>
<th>Dose</th>
<th>Timing</th>
<th>Mouse line</th>
<th>Efficiency</th>
</tr>
<tr>
<th colspan="7">Studies examining different doses of tamoxifen</th>
</tr>
<tr>
<th>Reference</th>
<th>PMID</th>
<th>Route</th>
<th>Dose</th>
<th>Timing</th>
<th>Mouse line</th>
<th>Readout</th>
</tr>
</thead>
<tbody>
<tr>
<td>(<a href="#bib13">Chen et al., 2009</a>)</td>
<td>19117051</td>
<td>IP to lactating mother</td>
<td>83.5 mg/kg body weight (BW)</td>
<td>Once a day for 5 consecutive days, starting from the day the pups are P0 or P7</td>
<td>Nestin73-CreERT2; Rosa26-LSL(loxP-Stop-loxP)-LacZ</td>
<td>X-gal labeling was observed in the whole cerebellum</td>
</tr>
<tr>
<td>(<a href="#bib13">Chen et al., 2009</a>)</td>
<td>19117051</td>
<td>IP</td>
<td>83.5 mg/kg BW</td>
<td>Twice a day for 5 consecutive days in 4- or 8-week old mice</td>
<td>Nestin73-CreERT2; Rosa26-LSL-EYFP, Nestin73-CreERT2; Rosa26-LSL-LacZ</td>
<td>75 ± 4% of Sox2-positive cells in the subventricular zone have been targeted in mice injected tamoxifen from 4-weeks old.</td>
</tr>
<tr>
<td>
<a href="#bib10">Pitulescu et al. (2010</a>)</td>
<td>20725067</td>
<td>IP</td>
<td>50 μg (25 mg/kg BW in 2 g mouse)</td>
<td>Once a day for 3 consecutive days from P1</td>
<td>Cdh5-CreERT2; Efnb-flox; ROSA26-LSL-EYFP</td>
<td>Robust Cre-mediated recombination was observed in IB4-positive retinal vasculature</td>
</tr>
<tr>
<td>
<a href="#bib10">Pitulescu et al. (2010</a>)</td>
<td>20725067</td>
<td>IP</td>
<td>100 μg (33 mg/kg BW in 3 g mouse)</td>
<td>Once a day for 4 consecutive days from P5</td>
<td>Cdh5-CreERT2; Efnb-flox; ROSA26-LSL-EYFP</td>
<td>N/A</td>
</tr>
<tr>
<td>
<a href="#bib10">Pitulescu et al. (2010</a>)</td>
<td>20725067</td>
<td>IP</td>
<td>500 μg (16 mg/kg in 30 g mouse)</td>
<td>Once a day for 5 consecutive days in adult (&gt;8 weeks)</td>
<td>Cdh5-CreERT2; Efnb-flox; ROSA26-LSL-EYFP</td>
<td>N/A</td>
</tr>
<tr>
<td>(<a href="#bib14">Petrik et al., 2013</a>)</td>
<td>23991155</td>
<td>IP to lactating mother</td>
<td>150 mg/kg BW</td>
<td>Once a day for 3 consecutive days from P2</td>
<td>Nestin-CreERT2; Rosa26-LSL-EYFP</td>
<td>60% of pups showed YFP-positive cells in the brain</td>
</tr>
<tr>
<td>(<a href="#bib14">Petrik et al., 2013</a>)</td>
<td>23991155</td>
<td>IP to lactating mother and PO to pups</td>
<td>150 mg/kg BW</td>
<td>Once a day for 3 consecutive days from P2</td>
<td>Nestin-CreERT2; Rosa26-LSL-EYFP</td>
<td>100% of pups showed YFP-positive cells in the brain</td>
</tr>
<tr>
<td>(<a href="#bib15">Huang et al., 2014</a>)</td>
<td>24578301</td>
<td>IP to lactating mother</td>
<td>100 mg/kg BW</td>
<td>Once a day for 2 consecutive days from P3 or P8</td>
<td>NG2-CreERT2; Rosa26-LSL-tdTomato</td>
<td>A large number of tdTomato-positive glia appeared in all brain regions</td>
</tr>
<tr>
<td>(<a href="#bib15">Huang et al., 2014</a>)</td>
<td>24578301</td>
<td>IP</td>
<td>1.2 mg in the morning and 1.5 mg 8 h later (40 mg/kg BW and 50 mg/kg BW in 30 g mouse each)</td>
<td>Twice a day for 5 consecutive days in young adult</td>
<td>NG2-CreERT2; Rosa26-LSL-EYFP</td>
<td>∼75% of NG2-positive glia were labeled by EYFP in dorsal cortex or corpus callosum in Rosa26-EYFP mice</td>
</tr>
<tr>
<td>(<a href="#bib15">Huang et al., 2014</a>)</td>
<td>24578301</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 5 consecutive days in young adult and aged</td>
<td>NG2-CreERT2; Rosa26-LSL-tdTomato</td>
<td>∼95% of NG2-positive glia were labeled by tdTomato in dorsal cortex or corpus callosum in Rosa26-tdTomato mice</td>
</tr>
<tr>
<td>(<a href="#bib16">Pohlkamp et al., 2014</a>)</td>
<td>24950299</td>
<td>IP</td>
<td>300 μg (150 mg/kg BW in 2 g mouse)</td>
<td>Once at P3</td>
<td>Nse-CreERT2; ROSA26-LSL-LacZ, Nse-CreERT2; ROSA26-tdTomato-flox-EGFP</td>
<td rowspan="2">Robust Cre-mediated recombination was observed in cerebellar granule cells. Efficiency was not quantified since granule cells are very tiny and densely packed.</td>
</tr>
<tr>
<td>(<a href="#bib16">Pohlkamp et al., 2014</a>)</td>
<td>24950299</td>
<td>IP</td>
<td>135 mg/kg BW</td>
<td>Once a day for 5 consecutive days in adult (&gt;2 months)</td>
<td>Nse-CreERT2; ROSA26-LSL-LacZ, Nse-CreERT2; ROSA26-tdTomato-flox-EGFP</td>
</tr>
<tr>
<td>
<a href="#bib1">Aida et al. (2015</a>)</td>
<td>25662838</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once at P1</td>
<td>GLAST-CreERT2; GLT1-flox</td>
<td>Almost complete deletion of GLT1 protein.</td>
</tr>
<tr>
<td>
<a href="#bib1">Aida et al. (2015</a>)</td>
<td>25662838</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 5 consecutive days from P19</td>
<td>GLAST-CreERT2; GLT1-flox, GLAST-CreERT2; ROSA26-LSL-tdTomato</td>
<td>Reduction of GLT1 protein by 60–80%. Almost all astrocytes expressed tdTomato.</td>
</tr>
<tr>
<td>
<a href="#bib1">Aida et al. (2015</a>)</td>
<td>25662838</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 5 consecutive days from P84</td>
<td>GLAST-CreERT2; GLT1-flox</td>
<td>Mild reduction of GLT1 protein.</td>
</tr>
<tr>
<td>
<a href="#bib5">Huang et al. (2018</a>)</td>
<td>30275311</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 10 days (5 doses) every other day from 3 weeks old</td>
<td>Ubc-CreERT2, LSL-Rai1</td>
<td>Cre-dependent removal of stop casset before the start codon restored <i>Rai1</i> mRNA to control level.</td>
</tr>
<tr>
<td>(<a href="#bib17">Diéguez-Hurtado et al., 2019</a>)</td>
<td>31249304</td>
<td>IP</td>
<td>50 μg (25 mg/kg BW in 2 g mouse)</td>
<td>Once a day for 3 consecutive days from P1</td>
<td>Pdgfrb-CreERT2; ROSA26-mTmG</td>
<td>Recombination efficiency in cortical regions of the cerebrum was around 80% and no obvious differences were found among distinct regions of the brain.</td>
</tr>
<tr>
<td>(<a href="#bib17">Diéguez-Hurtado et al., 2019</a>)</td>
<td>31249304</td>
<td>IP</td>
<td>1 mg (111 mg/kg BW in 9 g mouse)</td>
<td>Once a day for 5 consecutive days from P21 and older</td>
<td>Pdgfrb-CreERT2; ROSA26-mTmG</td>
<td>Efficient targeting of mural cells was achieved in juvenile and adult animals.</td>
</tr>
<tr>
<td>(<a href="#bib18">Ishii et al., 2021</a>)</td>
<td>33443207</td>
<td>IP</td>
<td>75 mg/kg BW</td>
<td>Once a day for 3 consecutive days from P3</td>
<td>Ift88-flox;ER81-CreERT2; ROSA26-LSL-tdTomato</td>
<td>Robust tdTomato expression at P8 in layer V neurons.</td>
</tr>
<tr>
<td>
<a href="#bib12">Valny et al. (2016</a>)</td>
<td>27812322</td>
<td>IP</td>
<td>200 mg/kg BW</td>
<td>Once a day for 2 consecutive days in P60-90 (for young adult)</td>
<td>C57BL6J (wild-type)</td>
<td rowspan="2">4-OHT concentration in brain is similar between 200 mg/kg and 100 mg/kg conditions</td>
</tr>
<tr>
<td>
<a href="#bib12">Valny et al. (2016</a>)</td>
<td>27812322</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 2 consecutive days in P60-90 (for young adult)</td>
<td>C57BL6J (wild-type)</td>
</tr>
<tr>
<td>
<a href="#bib7">Jahn et al. (2018</a>)</td>
<td>29651133</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once at P28</td>
<td>C57BL/6N (wild type), GLAST-CreERT2; glia1-flox; p2ry1-flox, GLAST-CreERT2; ROSA26-LSL-tdTomato</td>
<td rowspan="5">Three injections increased time required for clearance of tamoxifen and it's metabolites than one injection. Five days of 100 mg/kg tamoxifen IP reaches almost 100% recombination in astrocytes in the cerebral cortex and cerebellum.</td>
</tr>
<tr>
<td>
<a href="#bib7">Jahn et al. (2018</a>)</td>
<td>29651133</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 2 consecutive days from P28</td>
<td>GLAST-CreERT2; glia1-flox; p2ry1-flox</td>
</tr>
<tr>
<td>
<a href="#bib7">Jahn et al. (2018</a>)</td>
<td>29651133</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 3 consecutive days from P28</td>
<td>C57BL/6N (wild type), GLAST-CreERT2; glia1-flox; p2ry1-flox, GLAST-CreERT2; ROSA26-LSL-tdTomato</td>
</tr>
<tr>
<td>
<a href="#bib7">Jahn et al. (2018</a>)</td>
<td>29651133</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day for 5 consecutive days from P28</td>
<td>GLAST-CreERT2; glia1-flox; p2ry1-flox</td>
</tr>
<tr>
<td>
<a href="#bib7">Jahn et al. (2018</a>)</td>
<td>29651133</td>
<td>IP</td>
<td>100 mg/kg BW</td>
<td>Once a day, three doses every other day from P28</td>
<td>GLAST-CreERT2; glia1-flox; p2ry1-flox</td>
</tr>
<tr>
<td>
<a href="#bib2">Donocoff et al. (2020</a>)</td>
<td>32943672</td>
<td>IP</td>
<td>6 mg (200 mg/kg BW in 30 g mouse)</td>
<td>Once a day for 5 consecutive days in 8–20 weeks old</td>
<td>CAGGCre-ERTM; ROSA26-LSL-EYFP</td>
<td rowspan="4">6 mg tamoxifen IP showed higher tamoxifen concentration in liver/spleen, and mortality</td>
</tr>
<tr>
<td>
<a href="#bib2">Donocoff et al. (2020</a>)</td>
<td>32943672</td>
<td>IP</td>
<td>3 mg (100 mg/kg BW in 30 g mouse)</td>
<td>Once a day for 5 consecutive days in 8–20 weeks old</td>
<td>CAGGCre-ERTM; ROSA26-LSL-EYFP</td>
</tr>
<tr>
<td>
<a href="#bib2">Donocoff et al. (2020</a>)</td>
<td>32943672</td>
<td>PO</td>
<td>6 mg (200 mg/kg BW in 30 g mouse)</td>
<td>Once a day for 5 consecutive days in 8–20 weeks old</td>
<td>CAGGCre-ERTM; ROSA26-LSL-EYFP</td>
</tr>
<tr>
<td>(<a href="#bib2">Donocoff et al., 2020</a>)</td>
<td>32943672</td>
<td>PO</td>
<td>3 mg (100 mg/kg BW in 30 g mouse)</td>
<td>Once a day for 5 consecutive days in 8–20 weeks old</td>
<td>CAGGCre-ERTM; ROSA26-LSL-EYFP</td>
</tr>
</tbody>
</table>
<p>Age at which tamoxifen is administered may affect recombination efficiency (<a href="#tbl1">Table 1</a>). A single administration of 100 mg/kg BW of tamoxifen to GLAST-CreERT2 mice at P1 led to an almost complete deletion of the target protein, glutamate transporter 1. However, five daily administrations to P19 and adult mice led to a moderate or mild reduction, respectively (<a href="#bib1">Aida et al., 2015</a>). For neonatal mice, Pitulescu et al. intraperitoneally injected 50 μg tamoxifen for 3 consecutive days from P1 (equivalent to 25 mg/kg BW in a 2 g mouse), and 100 μg tamoxifen for 4 consecutive days from P5 (equivalent to 33 mg/kg BW in a 3 g mouse) (<a href="#bib10">Pitulescu et al., 2010</a>, <a href="#bib11">2017</a>).</p>
<p>After preliminary experiments, we decided to administer 100 mg/kg BW tamoxifen once a day for five days from P28. For infants, we repeatedly injected 500 μg tamoxifen at P14, 17, 20 to minimum intervention of pup rearing. Given that pups weigh 6g, 500ug is equivalent to 83 mg/kg BW.</p>
<h3 id="sec1.2">Animals</h3>
<p>All animal experiments must be approved by relevant institutional review board. The animal experiments described here were approved and conducted according to the guidelines established by the Institutional Animal Care and Use Committee of the University of Tsukuba.</p>
<p>We use <i>synapsin1</i><sup><i>CreERT2</i></sup> mouse line and <i>Sik3</i><sup><i>ex13flox</i></sup> mice in step-by-step protocol which were established in (<a href="#bib6">Iwasaki et al., 2021</a>). In <i>synapsin1</i><sup><i>CreERT2</i></sup>; <i>Sik3</i><sup><i>ex13flox</i></sup> mice, tamoxifen administration induces exon 13 skipping allele of Sik3, which produces Sleepy (Slp) mutant SIK3. Male mice were used in this protocol. EEG/EMG recording were performed between 10- to 12-week-old.</p>
<p>To breed mouse lines, genotyping is required. The reagents and primer information used in (<a href="#bib6">Iwasaki et al., 2021</a>) are shown in <a href="#key-resources-table">key resources table</a>. PCR cycling conditions are shown below. In genotyping of <i>synapsin1</i><sup><i>CreERT2</i></sup>, the size of PCR products of wild-type allele amplified with synapsin1-CreERT2_C1 and synapsin1-CreERT2_W1 is 396 bp, and knock-in allele amplified with synapsin1-CreERT2_C1 and synapsin1-CreERT2_M1 is 443 bp. In genotyping of <i>Sik3</i><sup><i>ex13flox</i></sup>, the size of PCR products of wild-type allele is 191 bp, and knock-in allele is 293 bp.</p>
<table id="undtbl1">
<caption>PCR cycling conditions for genotyping <i>synapsin1</i><sup><i>CreERT2</i></sup>
</caption>
<thead>
<tr>
<th>Steps</th>
<th>Temperature</th>
<th>Time</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Denaturation</td>
<td>94°C</td>
<td>3 min</td>
<td>1</td>
</tr>
<tr>
<td>Denaturation</td>
<td>94°C</td>
<td>30 s</td>
<td rowspan="3">40 cycles</td>
</tr>
<tr>
<td>Annealing</td>
<td>60°C</td>
<td>30 s</td>
</tr>
<tr>
<td>Extension</td>
<td>72°C</td>
<td>30 s</td>
</tr>
<tr>
<td>Final extension</td>
<td>72°C</td>
<td>5 min</td>
<td>1</td>
</tr>
<tr>
<td>Hold</td>
<td>4°C</td>
<td colspan="2">forever</td>
</tr>
</tbody>
</table>
<table id="undtbl2">
<caption>PCR cycling conditions for genotyping <i>Sik3</i><sup><i>ex13flox</i></sup>
</caption>
<thead>
<tr>
<th>Steps</th>
<th>Temperature</th>
<th>Time</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Denaturation</td>
<td>94°C</td>
<td>3 min</td>
<td>1</td>
</tr>
<tr>
<td>Denaturation</td>
<td>94°C</td>
<td>30 s</td>
<td rowspan="3">35 cycles</td>
</tr>
<tr>
<td>Annealing</td>
<td>60°C</td>
<td>30 s</td>
</tr>
<tr>
<td>Extension</td>
<td>72°C</td>
<td>30 s</td>
</tr>
<tr>
<td>Final extension</td>
<td>72°C</td>
<td>5 min</td>
<td>1</td>
</tr>
<tr>
<td>Hold</td>
<td>4°C</td>
<td colspan="2">forever</td>
</tr>
</tbody>
</table>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> This protocol can be applied to other CreERT2 and flox mouse lines. We recommend that you observe the spatial and temporal expressions of the target gene using Allen Brain Atlas and in situ hybridization before generating new CreERT2 mouse lines. It is recommended to verify enough recombination efficiency is achieved and consider dose/timing of tamoxifen administration as needed. Please refer prior part “Tamoxifen dosage” for protocol modification. To show spatial recombination pattern in expected outcomes, we used <i>ROSA26</i><sup><i>LacZ</i></sup> mouse line in (<a href="#bib6">Iwasaki et al., 2021</a>).</div>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> Adeno-associated virus (AAV)-based approaches are also possible to induce a mutant allele in the adult brain. For example, the local administration of Cre-expressing AAV in <i>Sik3</i><sup><i>ex13flox</i></sup> mouse brains can induce the exon 13-skipping allele. The local administration of a double-inverted orientation (DIO) of <i>Sik3 Slp (ex13-skipped)</i>-expressing AAV in an appropriate Cre mouse brains enables to express the mutant protein at a specific cell type.</div>
<h3 id="sec1.3">Preparation of materials required for EEG/EMG recording</h3>
<p>We examined sleep/wake behavior using electroencephalogram/electromyogram (EEG/EMG) recording after CreERT2 induction. Specialized equipment is required such as recording chambers, stereotaxic apparatus, EEG/EMG electrodes, amplifiers and analog-to-digital converters, EEG/EMG analysis software. Protocol to make tether cable is shown below. Please refer to <a href="#key-resources-table">key resources table</a> for equipment information.</p>
<div class="timing">
<span class="timing-title">Timing:</span> 1 day</div>
<p>Preparation of tether cable</p>
<ol>
<li>Cable preparation
<ol type="a">
<li>Prepare tools and materials shown in <a href="#fig1">Figures 1</a>A and 1B.
<figure id="fig1"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig1.jpg" alt="Fig1.jpg">
<figcaption>
<div class="figcaption-title">Figure 1. Tether cable preparation</div>
<p>(A) Tools for tether cable preparation.</p>
<p>(B) Materials of tether cable.</p>
<p>(C) An end of four-core tether cable of which the intervention and shield are removed and inner sheath are stripped.</p>
<p>(D) Each wire passing through narrow heat-shrinkable tubes.</p>
<p>(E) Four-core cable assembled with 8 narrow heat-shrinkable tubes and 2 thick heat-shrinkable tubes.</p>
<p>(F) Detangler cable of which inner sheath are stripped.</p>
<p>(G) Conductors of detangler and four-core cable are in contact with each other in narrow heat-shrinkable tube.</p>
<p>(H) Wires of detangler and four-core cable are connected after hot air is applied.</p>
<p>(I) Shorter pins and conductors of four-core cable are in contact with each other in narrow heat-shrinkable tube. Allocation of EEG/EMG among pins are shown in schematic image.</p>
<p>(J) Shorter pins and four-core cable are connected after hot air is applied.</p>
<p>(K) Epoxy resin is applied from the outer sheath to the base of the electrode pins.</p>
<p>(L) Thick heat-shrinkable tube covering the border between sheath and wires after sealing.</p>
<p>(M) Epoxy resin is applied to the connections between heat-shrinkable tube and four-core cable, and heat-shrinkable tube to the base of the electrode pins.</p>
<p>(N) Epoxy resin is applied to the connections between the detangler cable and heat-shrinkable tube, and heat-shrinkable tube and four-core cable.</p>
<p>(O) A hanger wire is attached to the detangler. Finished tether cable.</p>
</figcaption>
</figure>
</li>
<li>Cut the four-core cable into 17 cm pieces.</li>
<li>Strip 1–1.2 cm of the outer sheath from both ends of the four-core cable with a stripper.</li>
<li>Cut the metallic shields and intervention of the four-core cable from each end with small scissors</li>
<li>Strip 1–1.2 mm of the inner sheath from each end of the four wires with a wire stripper (<a href="#fig1">Figure 1</a>C).</li>
<li>Prepare eight thin heat-shrinkable tubes of 1 cm in length and two thick heat-shrinkable tubes of 2 cm in length (<a href="#fig1">Figure 1</a>B).</li>
<li>Pass each wire through the thin heat-shrinkable tube (<a href="#fig1">Figure 1</a>D).</li>
<li>Pass the cable through the two thick heat-shrinkable tubes (<a href="#fig1">Figure 1</a>E).</li>
</ol>
</li>
<li>Detangler preparation
<ol type="a">
<li>Cut the detangler cable.</li>
<li>Strip the outer sheath of the detangler cable from the end with small scissors.</li>
<li>Strip 1–1.2 mm of the inner sheath from the four wires of the detangler cable using a wire stripper (<a href="#fig1">Figure 1</a>F).</li>
</ol>
</li>
<li>Prepare electrode pins
<ol type="a">
<li>Bend the pin headers with pliers and cut it so that each piece has three pairs of electrode pins (<a href="#fig1">Figure 1</a>B).</li>
</ol>
</li>
</ol>
<ol start="4">
<li>Attach the four-core cable to the detangler cable
<ol type="a">
<li>Insert each detangler wire into the thin heat-shrinkable tube covering a specific wire (<a href="#fig1">Figure 1</a>G).
<div class="critical">
<span class="critical-title">Critical:</span> The conductors of the four-core cable and the detangler cable need to be in contact with each other.</div>
</li>
<li>Apply hot air to the heat-shrinkable tubes with a heat gun to shrink them (<a href="#fig1">Figure 1</a>H).
<div class="note">
<span class="note-title">Note:</span> Do not expose the thick heat-shrinkable tube to hot air.</div>
</li>
</ol>
</li>
</ol>
<ol start="5">
<li>Connect the four-core cable to the electrode pins to make a tether cable
<ol type="a">
<li>Insert each pin into the thin heat-shrinkable tube covering a specific wire (<a href="#fig1">Figure 1</a>I).
<div class="critical">
<span class="critical-title">Critical:</span> The conductors of the four-core cable and the electrode pins need to be in contact with each other.</div>
</li>
<li>Apply hot air to the thin heat-shrinkable tubes with a heat gun to shrink them (<a href="#fig1">Figure 1</a>J).
<div class="note">
<span class="note-title">Note:</span> Do not expose the thick heat-shrinkable tube to hot air.</div>
</li>
</ol>
</li>
</ol>
<ol start="6">
<li>Check energization
<ol type="a">
<li>Connect the tether cable to the multimeter tester with electrode pins and detangler.</li>
<li>Make sure that the electrical resistance of all conductors are less than 20Ω and stable even when the detangler is twisted.</li>
</ol>
</li>
<li>Fix connections with epoxy and attach hanger wire
<ol type="a">
<li>Fix the pins and cable connection with epoxy.
<ol type="i">
<li>Mix the two components of the epoxy resin.</li>
<li>Apply the mixed epoxy resin from the outer sheath to the base of the electrode pins and leave it until it hardens (<a href="#fig1">Figure 1</a>K).</li>
<li>Cover the border between sheath and wires with thick heat-shrinkable tube and seal it (<a href="#fig1">Figure 1</a>L).</li>
<li>Apply the mixed epoxy resin to the connections between heat-shrinkable tube and four-core cable, and heat-shrinkable tube to the base of the electrode pins. Leave it until it hardens (<a href="#fig1">Figure 1</a>M).</li>
</ol>
</li>
<li>Fix the detangler and cable connection with epoxy.
<ol type="i">
<li>Cover the connection from the four-core cable to the detangler cable with a thick heat-shrinkable tube and shrink it with a heat gun.</li>
<li>Apply the mixed epoxy resin to the connections between the detangler cable and heat-shrinkable tube, and heat-shrinkable tube and four-core cable. Leave it until it hardens (<a href="#fig1">Figure 1</a>N).</li>
</ol>
</li>
<li>Attach a hanger wire to the detangler (<a href="#fig1">Figure 1</a>O).</li>
</ol>
</li>
</ol>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> There are several ways to assess sleep/wakefulness without EEG/EMG recording. However, EEG/EMG-based sleep analysis is the most reliable, especially for rapid eye movement sleep (REM sleep) and enables spectrum analysis that is required for the deeper analysis of sleep.</div>
</section>
<section>
<h2 id="key-resources-table">Key resources table</h2>
<table id="krt">
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Antibodies</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-Sik3 C-terminus (1:2000)</td>
<td>(<a href="#bib3">Funato et al., 2016</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-SIK3 ex13 (1:2000)</td>
<td>(<a href="#bib4">Honda et al., 2018</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-Slp-specific SIK3 (1:2000)</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>β-Tubulin (9F3) Rabbit mAb (1:1000)</td>
<td>Cell Signaling</td>
<td>2128</td>
</tr>
<tr>
<td>Peroxidase AffiniPure Donkey Anti-Rabbit IgG (H+L) (1:2000)</td>
<td>Jackson ImmunoResearch Laboratories</td>
<td>711-035-152</td>
</tr>
<tr>
<td colspan="3">Chemicals, peptides, and recombinant proteins</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Sigma-Aldrich</td>
<td>T5648</td>
</tr>
<tr>
<td>Corn oil</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>032-17016</td>
</tr>
<tr>
<td>Corn oil (alternative)</td>
<td>Sigma-Aldrich</td>
<td>C8267</td>
</tr>
<tr>
<td>Isoflurane</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>099-06571</td>
</tr>
<tr>
<td>1M Tris-HCl pH7.6</td>
<td>Nacalai Tesque</td>
<td>35436-01</td>
</tr>
<tr>
<td>NaCl</td>
<td>Nacalai Tesque</td>
<td>31320-05</td>
</tr>
<tr>
<td>PhosSTOP</td>
<td>Roche Diagnostics</td>
<td>4906837001</td>
</tr>
<tr>
<td>0.5mol EDTA</td>
<td>Nacalai Tesque</td>
<td>06894-14</td>
</tr>
<tr>
<td>Phosphatase Inhibitor Cocktail2</td>
<td>Sigma-Aldrich</td>
<td>P5726</td>
</tr>
<tr>
<td>Protease inhibitor</td>
<td>TaKaRa</td>
<td>Z5673N</td>
</tr>
<tr>
<td>Sodium dodecyl sulfate</td>
<td>Sigma-Aldrich</td>
<td>L3771-100G</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Nacalai Tesque</td>
<td>30404-45</td>
</tr>
<tr>
<td>Bromophenol Blue</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>029-02912</td>
</tr>
<tr>
<td>Trizma base (Tris)</td>
<td>Sigma-Aldrich</td>
<td>T1503-1KG</td>
</tr>
<tr>
<td>2-Mercaptoethanol</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>133-14571</td>
</tr>
<tr>
<td>Acrylamide</td>
<td>Nacalai Tesque</td>
<td>06114-95</td>
</tr>
<tr>
<td>Bisacrylamide</td>
<td>Nacalai Tesque</td>
<td>22407-52</td>
</tr>
<tr>
<td>Ammonium Persulfate (APS)</td>
<td>Nacalai Tesque</td>
<td>06284-04</td>
</tr>
<tr>
<td>TEMED</td>
<td>Nacalai Tesque</td>
<td>33401-72</td>
</tr>
<tr>
<td>Glycine</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>072-05285</td>
</tr>
<tr>
<td>HCl</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>080-01066</td>
</tr>
<tr>
<td>Tween 20</td>
<td>Sigma-Aldrich</td>
<td>P9416-100ML</td>
</tr>
<tr>
<td>Methanol</td>
<td>FUJIFILM Wako Pure Chemical</td>
<td>137-01823</td>
</tr>
<tr>
<td>BSA</td>
<td>Sigma-Aldrich</td>
<td>A6003-25G</td>
</tr>
<tr>
<td colspan="3">Critical commercial assays</td>
</tr>
<tr>
<td>Tissue Preparation Solution</td>
<td>Sigma-Aldrich</td>
<td>T3073-30ML</td>
</tr>
<tr>
<td>Neutralization Solution B</td>
<td>Sigma-Aldrich</td>
<td>N3910-24ML</td>
</tr>
<tr>
<td>RED Extract-N-Amp PCR Ready Mix</td>
<td>Sigma-Aldrich</td>
<td>R4775-125ML</td>
</tr>
<tr>
<td>Micro BCA assay</td>
<td>Thermo Fisher Scientific</td>
<td>23235</td>
</tr>
<tr>
<td>Clarity Western ECL Substrate</td>
<td>Bio-Rad Laboratories</td>
<td>170-5061</td>
</tr>
<tr>
<td colspan="3">Experimental models: Organisms/strains</td>
</tr>
<tr>
<td>Mouse: Syn1em1(cre/ERT2)Iiis or synapsin1CreERT2</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>MGI:6506975</td>
</tr>
<tr>
<td>Mouse: Sik3tm2.1Iiis or Sik3ex13flox</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>MGI:6506974</td>
</tr>
<tr>
<td colspan="3">Oligonucleotides</td>
</tr>
<tr>
<td>synapsin1-CreERT2_C1: GATCTGGAGGTGACCAGGAA</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>synapsin1-CreERT2_M1: AACAAAGGCATGGAGCATCT</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>synapsin1-CreERT2_W1: TGCCTCCACCTTGTCTCTCT</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>Sik3-ex13flox_SLloxF: CTCTGACAGTTCTGTTCCAG</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td>Sik3-ex13flox_SLloxR: TGCCAGGAGAGTAGGCAGAT</td>
<td>(<a href="#bib6">Iwasaki et al., 2021</a>)</td>
<td>N/A</td>
</tr>
<tr>
<td colspan="3">Software and algorithms</td>
</tr>
<tr>
<td>LabVIEW</td>
<td>National Instruments</td>
<td><a href="https://www.ni.com/en-us/shop/labview.html">https://www.ni.com/en-us/shop/labview.html</a></td>
</tr>
<tr>
<td>MATLAB</td>
<td>MathWorks</td>
<td><a href="https://www.mathworks.com/products/matlab.html">https://www.mathworks.com/products/matlab.html</a></td>
</tr>
<tr>
<td colspan="3">Other</td>
</tr>
<tr>
<td>Syringe (29G)</td>
<td>Terumo</td>
<td>SS-05M2913</td>
</tr>
<tr>
<td>Four-core cable</td>
<td>Mogami wire</td>
<td>AWG28</td>
</tr>
<tr>
<td>Heat-shrinkable tubeφ0.6 mm</td>
<td>Woer Heat Shrinkable Material</td>
<td>suc-351</td>
</tr>
<tr>
<td>Heat-shrinkable tubeφ5.0 mm</td>
<td>Sumitomo Electric Fine Polymer</td>
<td>C5B</td>
</tr>
<tr>
<td>Detangler</td>
<td>SANWA SUPPLY INC.</td>
<td>TEL-TW2 (Discontinued)</td>
</tr>
<tr>
<td>Detangler (alternative)</td>
<td>Phillips</td>
<td>SJA4150</td>
</tr>
<tr>
<td>Pin header</td>
<td>Useconn Electronics</td>
<td>C-00082</td>
</tr>
<tr>
<td>Epoxy resin</td>
<td>Cemedine</td>
<td>CA-193</td>
</tr>
<tr>
<td>Heat Gun</td>
<td>ISHIZAKI ELECTRIC</td>
<td>PJ-214A</td>
</tr>
<tr>
<td>Multimeter tester</td>
<td>CUSTOM corporation</td>
<td>CX-02</td>
</tr>
<tr>
<td>Wire stripper</td>
<td>ENGINEER Inc</td>
<td>PA-14</td>
</tr>
<tr>
<td>Plier</td>
<td>HOZAN</td>
<td>P-51</td>
</tr>
<tr>
<td>Stereotaxic instrument</td>
<td>David Kopf Instruments</td>
<td>Model 940</td>
</tr>
<tr>
<td>Ear bars</td>
<td>David Kopf Instruments</td>
<td>Model 921</td>
</tr>
<tr>
<td>Drill Holder</td>
<td>David Kopf Instruments</td>
<td>Model 1474</td>
</tr>
<tr>
<td>Implant holder</td>
<td>David Kopf Instruments</td>
<td>Model 1770</td>
</tr>
<tr>
<td>Leutor (mortar unit)</td>
<td>Nihon Seimitsu Kikai Kosaku Co.</td>
<td>LGII M-22</td>
</tr>
<tr>
<td>Leutor (Power unit)</td>
<td>Nihon Seimitsu Kikai Kosaku Co.</td>
<td>LGII C-22</td>
</tr>
<tr>
<td>Leutor (Foot switch)</td>
<td>Nihon Seimitsu Kikai Kosaku Co.</td>
<td>FS-12</td>
</tr>
<tr>
<td>Tungsten carbide drill bit</td>
<td>SHOFU</td>
<td>HP-2</td>
</tr>
<tr>
<td>Anesthetic gas vaporizer</td>
<td>Shinano Seisakusho</td>
<td>SN-487-0T Air</td>
</tr>
<tr>
<td>Anesthesia induction box</td>
<td>Shinano Seisakusho</td>
<td>SN-487-85-03</td>
</tr>
<tr>
<td>Anesthetic gas absorber</td>
<td>Shinano Seisakusho</td>
<td>SN-487-61</td>
</tr>
<tr>
<td>Anesthetic gas scavenging system</td>
<td>Shinano Seisakusho</td>
<td>SN-489-4</td>
</tr>
<tr>
<td>Ethicon Needle with suture</td>
<td>Johnson &amp; Johnson</td>
<td>W595</td>
</tr>
<tr>
<td>Dental cement</td>
<td>3M</td>
<td>RelyX Unicem 2</td>
</tr>
<tr>
<td>Surgery tools</td>
<td>Natsume Seisakusho</td>
<td>N/A</td>
</tr>
<tr>
<td>Multi-axis counter balanced lever arm</td>
<td>Instech Laboratories</td>
<td>MCLA</td>
</tr>
<tr>
<td>Hanger wire (as an accessory to the lever arm)</td>
<td>Instech Laboratories</td>
<td>MCLA</td>
</tr>
<tr>
<td>Recording cage</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Recording cage top</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Electrode</td>
<td>UNIQUE MEDICAL</td>
<td>(<a href="#bib8">Miyoshi et al., 2019</a>)</td>
</tr>
<tr>
<td>Preamplifier</td>
<td>Nihon Kohden</td>
<td>JB−641J</td>
</tr>
<tr>
<td>Amplifier</td>
<td>Nihon Kohden</td>
<td>AB-611J</td>
</tr>
<tr>
<td>AD converter</td>
<td>National Instruments</td>
<td>PCIe-6320</td>
</tr>
<tr>
<td>Vaseline</td>
<td>Kenei Phamaceutical</td>
<td>N/A</td>
</tr>
<tr>
<td>LED light</td>
<td>3M</td>
<td>Elipar S10</td>
</tr>
<tr>
<td>Silk thread</td>
<td>ETHICON</td>
<td>W595</td>
</tr>
<tr>
<td>Heating pad</td>
<td>Nissinrika</td>
<td>NHP-M30N</td>
</tr>
<tr>
<td>Liquid nitrogen</td>
<td>Cryogenics Div., Univ. of Tsukuba</td>
<td>N/A</td>
</tr>
<tr>
<td>Rotor-stator homogenizer</td>
<td>PRO Scientific</td>
<td>PRO200</td>
</tr>
<tr>
<td>PVDF membrane</td>
<td>Merck Millipore</td>
<td>IPVH00010</td>
</tr>
<tr>
<td>Chemiluminescence Imaging System</td>
<td>Vilber-Lourmat</td>
<td>Fusion Solo 6S.EDGE</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2 id="materials-and-equipment">Materials and equipment</h2>
<table id="undtbl3">
<caption>Lysis Buffer</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris-HCl pH7.6 (1 M)</td>
<td>50 mM</td>
<td>50 μL</td>
</tr>
<tr>
<td>NaCl (1 M)</td>
<td>150 mM</td>
<td>150 μL</td>
</tr>
<tr>
<td>EDTA (0.5 M)</td>
<td>1 mM</td>
<td>2 μL</td>
</tr>
<tr>
<td>Phosphatase Inhibitor Cocktail2</td>
<td>1%</td>
<td>10 μL</td>
</tr>
<tr>
<td>Protease Inhibitor</td>
<td>1%</td>
<td>10 μL</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 1 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Prepare on ice before use.</div>
<table id="undtbl4">
<caption>6× Sample Buffer</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium dodecyl sulfate (SDS)</td>
<td>12%</td>
<td>1.2 g</td>
</tr>
<tr>
<td>Sucrose</td>
<td>30%</td>
<td>3 g</td>
</tr>
<tr>
<td>Bromophenol Blue</td>
<td>0.03%</td>
<td>3 mg</td>
</tr>
<tr>
<td>Tris-HCl pH6.8 (1 M)</td>
<td>0.375 M</td>
<td>3.75 mL</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 7 mL</td>
</tr>
<tr>
<td>2-mercaptoethanol</td>
<td>30%</td>
<td>3 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>10 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Add MilliQ after the other reagents are dissolved by heating at 70°C for 15 min; Store the aliquot at −20°C without 2-mercaptoethanol and can be store for at least 6 months; Add 2-mercaptoethanol immediately before use and store at 4°C.</div>
<table id="undtbl5">
<caption>30% Acrylamide Mix</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acrylamide</td>
<td>29.2%</td>
<td>14.6 g</td>
</tr>
<tr>
<td>Bisacrylamide</td>
<td>0.8%</td>
<td>0.4 g</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 50 mL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>50 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Store at 4°C protected from light, and do not store more than 6 months.</div>
<table id="undtbl6">
<caption>Running Gel (7%)</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>H<sub>2</sub>O</td>
<td>n/a</td>
<td>12.267 mL</td>
</tr>
<tr>
<td>30% Acrylamide Mix</td>
<td>7%</td>
<td>5.833 mL</td>
</tr>
<tr>
<td>Tris-HCl pH8.8 (1.5 M)</td>
<td>0.375 M</td>
<td>6.25 mL</td>
</tr>
<tr>
<td>SDS (10%)</td>
<td>0.1%</td>
<td>0.25 mL</td>
</tr>
<tr>
<td>Ammonium persulfate (APS)(10%)</td>
<td>0.15%</td>
<td>0.375 mL</td>
</tr>
<tr>
<td>TEMED</td>
<td>0.1%</td>
<td>25 μL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>25 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Add TEMED and mix immediately before pouring the gel into the mold.</div>
<table id="undtbl7">
<caption>Stacking Gel (3%)</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>H<sub>2</sub>O</td>
<td>n/a</td>
<td>5.912 mL</td>
</tr>
<tr>
<td>30% Acrylamide Mix</td>
<td>3%</td>
<td>0.8 mL</td>
</tr>
<tr>
<td>Tris-HCl pH6.8 (1 M)</td>
<td>0.125 M</td>
<td>1 mL</td>
</tr>
<tr>
<td>SDS (10%)</td>
<td>0.1%</td>
<td>80 μL</td>
</tr>
<tr>
<td>APS (10%)</td>
<td>0.25%</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>TEMED</td>
<td>0.1%</td>
<td>8 μL</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>8 mL</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Add TEMED and mix immediately before pouring the gel into the mold.</div>
<table id="undtbl8">
<caption>10× Running Buffer</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trizma base</td>
<td>250 mM</td>
<td>30.2 g</td>
</tr>
<tr>
<td>Glycine</td>
<td>1.92 M</td>
<td>144 g</td>
</tr>
<tr>
<td>SDS</td>
<td>1%</td>
<td>10 g</td>
</tr>
<tr>
<td>MilliQ</td>
<td>-</td>
<td>Up to 1 L</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Store at 18°C–24°C, and do not store more than 1 year. Dilute before use.</div>
<table id="undtbl9">
<caption>10× Transfer Buffer</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trizma base</td>
<td>250 mM</td>
<td>30.2 g</td>
</tr>
<tr>
<td>Glycine</td>
<td>1.92 M</td>
<td>144 g</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 1 L</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Store at 18°C–24°C, and do not store more than 1 year. Dilute before use.</div>
<table id="undtbl10">
<caption>10× TRIS Buffered Saline (TBS)</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trizma base</td>
<td>0.5 M</td>
<td>60.57 g</td>
</tr>
<tr>
<td>NaCl</td>
<td>1.5 M</td>
<td>87.66 g</td>
</tr>
<tr>
<td>HCl (12 M)</td>
<td>n/a</td>
<td>15–20 mL (adjust at pH7.6)</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 1 L</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Store at 18°C–24°C, and do not store more than 1 year.</div>
<table id="undtbl11">
<caption>1× TBST</caption>
<thead>
<tr>
<th>Reagents</th>
<th>Final concentration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>10× TBS</td>
<td>1×</td>
<td>100 mL</td>
</tr>
<tr>
<td>Tween 20 (10%)</td>
<td>0.1%</td>
<td>10 mL</td>
</tr>
<tr>
<td>MilliQ</td>
<td>n/a</td>
<td>Up to 1 L</td>
</tr>
<tr>
<td><b>Total</b></td>
<td><b>n/a</b></td>
<td><b>1 L</b></td>
</tr>
</tbody>
</table>
<div class="note">
<span class="note-title">Note:</span> Store at 18°C–24°C, and do not store more than 2 weeks.</div>
<h3 id="sec2.1">Materials to confirm CreERT2 dependent recombination</h3>
<h4 id="sec2.1.1">Western blots using allele specific antibodies</h4>
<p>In general, useful antibodies for detecting allele induction or deletion are as follows: 1) antibodies specific for sequences deleted by Cre-dependent allele induction/deletion; 2) antibodies specific for sequences encompassing adjacent exons after Cre-dependent allele induction/deletion. 3) antibodies specific for functional features such as amino acid sequence containing phosphorylated amino acids. Standard equipment for western blots is required. Please refer <a href="#key-resources-table">key resources table</a> for product information that we used in the protocol.</p>
<h4 id="sec2.1.2">Anti-SIK3 ex13 antibody</h4>
<p>This rabbit polyclonal antibody was raised against LHAQQLLKRPRGPS using custom antibody production (Eurofins). The amino acid sequence is encoded by exon 13 and is expected to be less susceptible to phosphorylation because it is 8 amino acids away from 551 serine residue.</p>
<h4 id="sec2.1.3">Anti-Slp-specific SIK3 antibody</h4>
<p>This rabbit polyclonal antibody was raised against QLEYKAVPA spanning the sequence encoded by exon12 and exon 14 using custom antibody production (Eurofins). Resultant anti-serum was absorbed with QLEYKEQS (synthesized by Eurofins) spanning the sequence encoded by exon12 and exon 13 to eliminate the affinity for wild-type SIK3.</p>
<p>SIK3 sequence a part of exon12, 13, 14-encoded regions. QVAPNMNFTHNLLPMQSLQPTGQLEYK<b>EQSLLQPPTLQLLNGMGPLG<u>RRAS</u>DGGANIQLHAQQLLKRPRGPSPLVTMTP</b>AVPAVTPVDEESSDGEPDQEA</p>
<p>Bold letters indicate amino acids encoded by exon 13 and RRAD (underlined) is the consensus sequence for PKA phosphorylation.</p>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> Alternative antibody is required depending on the flox mouse line. Consider RT-PCR if there is no available antibody.</div>
</section>
<section>
<h2 id="step-by-step-method-details">Step-by-step method details</h2>
<h3 id="sec3.1">Obtaining <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox</i></sup> mice</h3>
<div class="timing">
<span class="timing-title">Timing:</span> More than 4 weeks</div>
<p><i>Synapsin1</i><sup><i>CreERT2</i></sup> and <i>Sik3</i><sup><i>ex13flox</i></sup> mice are crossed to obtain <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox</i></sup> mice. <b>Since the <i>synapsin1</i> gene is located on the X chromosome, the <i>synapsin1</i></b><sup><b><i>CreERT2</i></b></sup> <b>of males is passed from their mothers.</b> In order to increase efficiency, it is necessary to increase the number of mice with the appropriate sex and genotype. Young adult mice (2–4 months) are recommended when breeding starts.</p>
<ol>
<li>Obtain homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females. Following steps a and b shows how to obtain females with homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup>, which resides X chromosome, from a heterozygous mouse. When you do not have homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females, please refer a and b.
<ol type="a">
<li>Cross <i>synapsin1</i><sup><i>CreERT2</i></sup> knock-in mice with wild-type mice of the opposite sex to obtain both heterozygous or homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females and hemizygous <i>synapsin1</i><sup><i>CreERT2</i></sup> males.</li>
<li>Cross a heterozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> female and a hemizygous <i>synapsin1</i><sup><i>CreERT2</i></sup> male to obtain homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females.</li>
</ol>
</li>
<li>Cross homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females and a heterozygous <i>Sik3</i><sup><i>flox</i></sup> male mouse to obtain male <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox</i></sup> mice.</li>
</ol>
<div class="critical">
<span class="critical-title">Critical:</span> Appropriate regulations and guidelines for mouse experiments must be followed.</div>
<div class="critical">
<span class="critical-title">Critical:</span> The <i>synapsin1</i> gene is located on the X chromosome. Since the <i>synapsin1</i><sup><i>CreERT2</i></sup> of male mice is passed from their mothers, if you plan to use male mice for your experiment, heterozygous or homozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> females are necessary to obtain hemizygous <i>synapsin1</i><sup><i>CreERT2</i></sup> males.</div>
<ol start="3">
<li>Check vaginal plugs every morning during breeding.</li>
<li>Transfer a pregnant female mouse to a separate cage in the case of polygamous mating.</li>
<li>Check daily to see if the female has given birth.</li>
<li>Record the date of birth.</li>
<li>Genotype the pups with Tissue Preparation Solution, Neutralization Solution B, and RED Extract-N-Amp PCR Ready Mix.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> To see the effect of SIK3 SLP (exon 13-skipped) allele induction, we compared heterozygous <i>synapsin1</i><sup><i>CreERT2</i></sup> males with <i>Sik3</i><sup><i>ex13flox</i></sup> allele to those without <i>Sik3</i><sup><i>ex13flox</i></sup> allele (<a href="#bib6">Iwasaki et al., 2021</a>).</div>
<p>Littermates are recommended as control group because the genetic and environmental conditions can be identical except for the <i>Sik3</i><sup><i>ex13flox</i></sup> allele.</p>
<div class="note">
<span class="note-title">Note:</span> Please refer to the <a href="#key-resources-table">key resources table</a> for reagents used in the genotype, and PCR conditions</div>
<ol start="8">
<li>Wean at around 4 weeks of age.</li>
</ol>
<h3 id="sec3.2">Tamoxifen dilution</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2 days</div>
<p>Tamoxifen is diluted to 20 mg/mL in corn oil. Dilution should be started the day before the first IP injection. Dissolved tamoxifen should be used within 1 month in 4°C.</p>
<div class="critical">
<span class="critical-title">Critical:</span> Tamoxifen needs to be handled carefully according to safety data sheet because of the toxicity<b>.</b>
</div>
<ol start="9">
<li>Cover a 15 mL-tube with aluminum foil to protect it from light (<a href="#fig2">Figures 2</a>A and 2B).
<figure id="fig2"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig2.jpg" alt="Fig2.jpg">
<figcaption>
<div class="figcaption-title">Figure 2. Procedure of dissolving tamoxifen in corn oil</div>
<p>(A and B) Prepare a tube and cover it with aluminum foil.</p>
<p>(C) Weigh tamoxifen in the tube prepared tube in (A and B).</p>
<p>(D) Add warmed corn oil to tamoxifen.</p>
<p>(E) Tamoxifen in corn oil before overnight incubation.</p>
<p>(F) Corn oil in which tamoxifen is completely dissolved.</p>
</figcaption>
</figure>
</li>
<li>Bring tamoxifen to room temperature in a dark room and heat 5 mL of corn oil to 42°C.</li>
<li>Weigh 80 mg of tamoxifen in the tube prepared in step 10 (<a href="#fig2">Figure 2</a>C).</li>
<li>Add warmed 4 mL of corn oil to the tube and vortex (<a href="#fig2">Figures 2</a>D and 2E).</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Change the amount of tamoxifen dilution as needed.</div>
<ol start="13">
<li>Incubate overnight (≒12 h) at 42°C with shaking.</li>
<li>Vortex several times during overnight incubation.</li>
<li>After incubation, vortex until tamoxifen is completely dissolved (<a href="#fig1">Figure 1</a>F).</li>
<li>Store at 4°C until use.</li>
</ol>
<div class="critical">
<span class="critical-title">Critical:</span> Repeat vortex until no more tamoxifen particle are visible<b>.</b>
</div>
<h3 id="sec3.3">Tamoxifen injection during late infancy</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 7 days</div>
<p>Tamoxifen is delivered with IP injection</p>
<ol start="17">
<li>Dilute tamoxifen stock (20 mg/mL) 2 times with corn oil to 10 mg/mL.</li>
</ol>
<ol start="18">
<li>Intraperitoneally inject 50 μL tamoxifen in corn oil (10 mg/mL) to pups on postnatal days 14, 17, and 20.
<ol type="a">
<li>Fill a syringe with the tamoxifen solution and remove air in syringe (<a href="#fig3">Figures 3</a>A and 3B).
<figure id="fig3"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig3.jpg" alt="Fig3.jpg">
<figcaption>
<div class="figcaption-title">Figure 3. IP injection to P14 mice</div>
<p>(A) Fill corn oil to syringe.</p>
<p>(B) Remove air from syringe in plastic bag (to prevent scatter of tamoxifen and be discarded to medical pale).</p>
<p>(C) Gently pinch pup’s back and keep tail between your fingers.</p>
<p>(D) Insert the needle about 5 mm to the lower abdomen.</p>
</figcaption>
</figure>
<div class="note">
<span class="note-title">Note:</span> Because of the high viscosity of corn oil, this step takes several minutes.</div>
</li>
<li>Separate pups to a new cage.</li>
<li>Gently stretch the pup along your hand by holding the back neck skin and tail (<a href="#fig3">Figure 3</a>C).</li>
<li>Insert the needle to the lower abdomen towards the head at a 30° to horizontal. The needle was inserted only 5 mm (<a href="#fig3">Figure 3</a>D).</li>
<li>Inject 50 μL of tamoxifen in corn oil intraperitoneally.</li>
<li>Put the pups back to breeding cage.
<div class="note">
<span class="note-title">Note:</span> This injection procedure is the same as giving an IP injection to an adult mouse.</div>
<div class="note">
<span class="note-title">Note:</span> It is recommended to fix injection time to avoid varying injection interval which may affect tamoxifen accumulation.</div>
<div class="note">
<span class="note-title">Note:</span> For histological examination, we sacrificed the mice 7–8 days after the last injection.</div>
</li>
</ol>
</li>
</ol>
<h3 id="sec3.4">EEG/EMG recording</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–3 weeks</div>
<p>EEG/EMG electrode implantation surgery, EEG/EMG recording and analysis is performed (<a href="#bib6">Iwasaki et al., 2021</a>; <a href="#bib8">Miyoshi et al., 2019</a>). Here, we show the procedure of EEG/EMG implantation surgery. In our laboratory, EEG signals are recorded from ipsilateral metal pins on left hemisphere, and EMG signals are obtained from neck extensor muscle.</p>
<ol start="19">
<li>EEG/EMG electrode implantation
<ol type="a">
<li>Prepare tools for electrode implantation (<a href="#fig4">Figure 4</a> and its figure legend).
<figure id="fig4"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig4.jpg" alt="Fig4.jpg">
<figcaption>
<div class="figcaption-title">Figure 4. Tools for EEG/EMG electrode implantation</div>
<p>(A) Tools for electrode implantation. One side 6-pin header is used as a “cap” for an EEG/EMG electrode after the implantation surgery. The bottom pins of 6-pin header are attached to an EEG/EMG electrode and the top pins are holed with implant holder during surgery.</p>
<p>(B) Close-up pictures of EEG/EMG electrode.</p>
</figcaption>
</figure>
</li>
<li>Place an 8–9-week-old mouse in an anesthesia box and anesthetize for 3 min with 4% isoflurane.</li>
<li>Fix the mouse head in a stereotaxic instrument with two ear bars and a nose clamp. (<a href="#fig5">Figure 5</a>A).
<figure id="fig5"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig5.jpg" alt="Fig5.jpg">
<figcaption>
<div class="figcaption-title">Figure 5. EEG/EMG electrode implantation</div>
<p>(A) Head- fixed mice on stereotaxic apparatus.</p>
<p>(B) Cranium surface is exposed.</p>
<p>(C) Drilling 4 holes for EEG electrodes.</p>
<p>(D) Drilling coordination. Posterior holes locate (x, y) = (± 1.27 mm, just anterior side of lambdoid sutures) and anterior holes locate (x, y) = (± 1.27 mm, 5.03 mm anterior from posterior holes). (E) How to fit electrode implantation to the holder.</p>
<p>(F) Lower the electrode implantation.</p>
<p>(G) Fill dental cement between skull surface and electrode implant.</p>
<p>(H) EMG wires are inserted into neck extensor muscles.</p>
<p>(I) EMG wires are fixed with dental cement.</p>
<p>(J) Suture done.</p>
</figcaption>
</figure>
<div class="note">
<span class="note-title">Note:</span> Stable fixation capable of avoiding movement by drilling is required.</div>
</li>
<li>Decrease isoflurane concentration to 2%.
<div class="note">
<span class="note-title">Note:</span> Observe respiratory rate and decrease isoflurane concentration if it is unstable or too slow.</div>
</li>
<li>Apply Vaseline to the eyes, shave the fur from the top of the head, and disinfect the head skin with 70% ethanol.</li>
<li>Make a longitudinal incision (2 cm long) along the midline of the scalp.</li>
<li>Open the skin with four tissue clamps and clean the cranium surface with a cotton swab (<a href="#fig5">Figure 5</a>B).</li>
<li>Adjust the head holder to set bregma and lambda at the same dorsoventral and mediolateral level (<a href="#fig5">Figure 5</a>B).</li>
<li>Drill four holes in the skull for EEG electrodes and clean the skull surface with a cotton swab (<a href="#fig5">Figures 5</a>C and 5D).
<div class="critical">
<span class="critical-title">Critical:</span> Do not drill too deep so as not to damage the cerebral cortex. We use the tip of the drill reaching the outer surface of the skull as seen by the surgeon as a guide. But this varies depending on the drill used and needs to be adjusted for each researcher.</div>
</li>
<li>Attach the electrode to the implant holder with long pins (made of a pin header, <a href="#fig1">Figure 1</a>) of the 6-pin header (<a href="#fig5">Figure 5</a>E).</li>
<li>Lower the electrode pins into the holes under stereotaxic control until reach the four stoppers (small protrusion at the bottom of the implant to contact the skull) of the implant attach on the skull (<a href="#fig5">Figure 5</a>F).
<div class="critical">
<span class="critical-title">Critical:</span> Do not push the skull with the stopper.</div>
<div class="critical">
<span class="critical-title">Critical:</span> Of the four stoppers, at least two on the left side should be attached to the skull for EEG recording.</div>
<div class="critical">
<span class="critical-title">Critical:</span> When two stoppers on the left side is not attached to the skull because of displacement in horizontal direction of skull, correct the tilt with screws on the stereotaxic instrument.</div>
</li>
<li>Set the Z axis to zero and heighten the Z axis of the implant to 1.0 mm.</li>
<li>Apply dental cement between the skull and the electrode base (<a href="#fig5">Figure 5</a>G).
<div class="critical">
<span class="critical-title">Critical:</span> Turn off the surgical light as the dental cement is cured by strong light<b>.</b>
</div>
<div class="critical">
<span class="critical-title">Critical:</span> Make sure that the cement does not contain air when it is filled.</div>
</li>
<li>Lower the Z axis of the implant to zero and cure the dental cement with LED light.
<div class="note">
<span class="note-title">Note:</span> Remove cement adhered to the EMG wires</div>
</li>
<li>Cross the two EMG wires and insert them into neck extensor muscles under the fascia (<a href="#fig5">Figure 5</a>H).</li>
<li>Apply dental cement from the base of the wires to the intersection and cure the dental cement with LED light (<a href="#fig5">Figure 5</a>I).</li>
<li>Apply two-four stitches using silk thread (<a href="#fig5">Figure 5</a>J).
<div class="note">
<span class="note-title">Note:</span> Make sure there is no gap between the implant and the skin to prevent suture from being broken by the mouse.</div>
</li>
<li>Stop the anesthesia and remove the mouse from the stereotaxic instrument.</li>
<li>Remove the 6-pin header from the implant and then insert a one side 6-pin header (<a href="#fig6">Figure 6</a>A).
<figure id="fig6"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig6.jpg" alt="Fig6.jpg">
<figcaption>
<div class="figcaption-title">Figure 6. Mouse after the surgery</div>
<p>(A) The mouse released from stereotaxic apparatus. A one side 6-pin header is inserted in place of the 6-pin header with long pins.</p>
<p>(B) The mouse with tether cable in a recording cage. Tether cable is connected as shown in right schematic image. A, anterior; P, posterior; R, right; L, left.</p>
<p>(C) Recording environment. The tether cable is hanged by a multi-axis counter balanced lever arm.</p>
</figcaption>
</figure>
<div class="note">
<span class="note-title">Note:</span> Hold the implant, not the mouse head, when removing the 6-pin header and inserting the one side 6-pin header.</div>
</li>
<li>Carefully wipe Vaseline from eyes.</li>
<li>Place the mouse in the cage on the heating pad to keep it warm until the mouse starts normal behavior.</li>
</ol>
</li>
</ol>
<ol start="20">
<li>EEG/EMG recording
<ol type="a">
<li>Allow the mouse to recover for at least 5 days in a home cage.</li>
<li>Put the mouse in an anesthesia box (4% isoflurane) and wait until the mouse loses righting reflex. Take the mice from the anesthesia box and quickly remove the cap and attach a tether cable to the mouse.</li>
<li>Acclimate the mouse to the recording environment for at least 7 days (<a href="#fig7">Figures 7</a>B and 7C).
<figure id="fig7"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/1218-Fig7.jpg" alt="Fig7.jpg">
<figcaption>
<div class="figcaption-title">Figure 7. Sleep/wake behavior and mutant allele induction in tamoxifen administered synapsin1-CreERT2; Sik3-exon13 flox mice</div>
<p>(A) Timeline for tamoxifen treatment followed by EEG/EMG recording.</p>
<p>(B–D) Time spent in wake (B), NREM sleep (NREMS) (C), and REM sleep (REMS) (D) for 24 h in <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox/+</i></sup> mice that were administered tamoxifen or vehicle at P14, P17, and P20. One-way ANOVA followed by Tukey’s test; 13 mice per group. Data are mean ± SEM. ∗∗∗p&lt;0.001. For more information, please refer to the original paper (<a href="#bib6">Iwasaki et al., 2021</a>).</p>
<p>(E) Western blotting of brain homogenates. An antibody specific to ex13 skipping SIK3 detected the protein (asterisks) in tamoxifen administrated <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox/+</i></sup> mice and <i>Sik3</i><sup><i>Slp/Slp</i></sup> mice (top row). An antibody specific to the exon 13-encoded region detected wild-type SIK3 protein in tamoxifen- or vehicle-administered <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox/+</i></sup> mouse brains, but not in <i>Sik3</i><sup><i>Slp/Slp</i></sup> mouse brains (middle row). An antibody specific to SIK3 c-terminus detected long isoform of SIK3 (third row). In wild-type brains, there are two major isoforms of SIK3: short isoform (50–75 kDa, top and second row) and long isoform (150–250 kDa, third row) (<a href="#bib9">Park et al., 2020</a>). β-tubulin was used as a loading control (bottom row).</p>
</figcaption>
</figure>
<div class="note">
<span class="note-title">Note:</span> Left side electrodes are used for EEG recording, so the electrode pins with three wires need to be left side (<a href="#fig6">Figure 6</a>B).</div>
<div class="note">
<span class="note-title">Note:</span> We wait at least 14 days from EEG/EMG electrode implantation to EEG/EMG recording.</div>
</li>
<li>Obtain and analyze EEG/EMG signaling with LabVIEW and MATLAB. Recording equipment are shown in <a href="#key-resources-table">key resources table</a>. For more details of recording condition and analysis, please refer to <a href="#bib8">Miyoshi et al. (2019</a>) and <a href="#bib6">Iwasaki et al. (2021</a>).</li>
</ol>
</li>
</ol>
<h3 id="sec3.5">Western blotting for verification of recombination</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 3 days</div>
<p><i>Sik3</i> recombination was verified with western blotting. Mice were sacrificed after EEG/EMG recording for brain sampling.</p>
<ol start="21">
<li>Brain sampling for western blotting
<ol type="a">
<li>Prepare liquid nitrogen (LN2), tubes and dissection tools.</li>
<li>Quickly dissect the brain after cervical dislocation and freeze it in LN2.</li>
<li>Store at −80°C until homogenization.</li>
</ol>
</li>
</ol>
<div class="pause-point">
<span class="pause-point-title">Pause point:</span> frozen brain can be stored at −80°C for at least 3 months.</div>
<ol start="22">
<li>Western blotting
<ol type="a">
<li>Homogenize the brains using a rotor-stator homogenizer in ice-cold Lysis Buffer (100 μL Lysis Buffer for 1 mg brain).</li>
<li>Rotate 15 min at 4°C for 30 min.</li>
<li>Centrifuge at 17800×<i>g</i> at 4°C for 12 min.</li>
<li>Immediately aliquot supernatant.</li>
<li>Determine protein concentration with micro BCA assay.</li>
<li>Dilute a part of supernatant with 6× Sample Buffer for SDS-PAGE and store the diluted sample and remaining sample at −80°C.
<div class="pause-point">
<span class="pause-point-title">Pause point:</span> frozen supernatants can be stored at −80°C.</div>
</li>
<li>Perform SDS-PAGE with 7% Running Gel (under the 3% Stacking Gel layer) with 50 μg of protein in 1× Running Buffer.</li>
<li>Activate PVDF membrane with methanol for 10 min at room temperature (18°C–24°C).</li>
<li>Transfer the protein to PVDF membranes in 1× Transfer Buffer.
<div class="note">
<span class="note-title">Note:</span> The concentration of acrylamide gel and protein concentration can be modified depending on your purpose.</div>
</li>
<li>Wash the membranes in TBST and incubate overnight (12–18 h) at 4°C with a primary antibody in TBST with 5% BSA.</li>
<li>Wash in TBST and incubate with HRP-conjugated for 2 h at room temperature (18°C–24°C), donkey anti-rabbit IgG (1:2000 dilution in TBST with 5% BSA; Jackson ImmunoResearch Laboratories)</li>
<li>Wash in TBST and expose the blots to Clarity Western ECL Substrate.</li>
<li>Detect chemiluminescence signaling with FUSION Solo 6S.EDGE.</li>
</ol>
</li>
</ol>
</section>
<section>
<h2 id="expected-outcomes">Expected outcomes</h2>
<p>By following the protocol described here, we analyzed sleep/wake behavior of mice expressing SIK3 lacking exon 13 encoded region in neurons after late infancy (<a href="#fig7">Figure 7</a>A). Total wake time was decreased and NREM sleep time was increased in tamoxifen administered <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox/+</i></sup> mice (<a href="#fig7">Figures 7</a>B and 7C), but REM sleep time remained unchanged (<a href="#fig7">Figure 7</a>D). These result shows that <i>CreERT2</i> knock-in to <i>synapsin1</i> locus did not affect total time spent in each stage. Western blotting showed that SIK3 lacking exon 13 expressed in <i>synapsin1</i><sup><i>CreERT2</i></sup><i>; Sik3</i><sup><i>ex13flox/+</i></sup> mice only with tamoxifen administration (<a href="#fig7">Figure 7</a>E, <a href="#bib6">Iwasaki et al., 2021</a>).</p>
</section>
<section>
<h2 id="limitations">Limitations</h2>
<p>The target exon that encodes functionally relevant amino acid sequence such as protein kinase recognition sequences is in-frame. Since the expression of <i>synapsin 1</i> is not evenly expressed in all neurons in the brain and tend to be more broadly expressed in earlier stage as shown (<a href="#bib6">Iwasaki et al., 2021</a>), the injection schedule of tamoxifen needs to be optimized.</p>
</section>
<section>
<h2 id="troubleshooting">Troubleshooting</h2>
<h3 id="sec6.1">Problem 1</h3>
<p>Tamoxifen does not dissolve in corn oil (step 15).</p>
<h3 id="sec6.2">Potential solution</h3>
<p>Increase the frequency of vortex during overnight incubation. Many protocols state that tamoxifen is dissolved at 37°C, but in our experience, that doesn't dissolve very well. Then, we set the temperature to 42°C to make it easier to dissolve. Please see <a href="#fig2">Figures 2</a>E and 2F.</p>
<h3 id="sec6.3">Problem 2</h3>
<p>Mice are dead after tamoxifen administration (step 18).</p>
<h3 id="sec6.4">Potential solution</h3>
<p>We have rarely experienced death of mice after tamoxifen administration in the current protocol. However, if mice frequently die after tamoxifen administration, the route and timing of administration should be changed appropriately to maintain a balance between the efficiency of Cre-dependent recombination and the survival rate. Please refer “Tamoxifen doseage” in this protocol for more information.</p>
<h3 id="sec6.5">Problem 3</h3>
<p>Bleeding from the skull hole during the implantation surgery (step 19. i).</p>
<h3 id="sec6.6">Potential solution</h3>
<p>Apply a clean twisted paper (kimwipes) into the skull hole and absorb the blood. In case of a lot of bleeding, apply pressure with a cotton swab against the skull hole to stop the bleeding.</p>
<h3 id="sec6.7">Problem 4</h3>
<p>The implant dislodged from the skull after the implantation surgery (step 19. k).</p>
<h3 id="sec6.8">Potential solution</h3>
<p>Before applying dental cement, carefully remove the blood and tissues on the skull with cotton swab.</p>
<h3 id="sec6.9">Problem 5</h3>
<p>The tether cord restricts mouse’s movement since the mouse is small or weak (step 20. c).</p>
<h3 id="sec6.10">Potential solution</h3>
<p>Using a thinner and softer tether will make it easier for the mouse to move. However, the tethers are weak, so always have spare tethers available, or change to a regular tether when the mouse grows.</p>
<h3 id="sec6.11">Problem 6</h3>
<p>The clean EEG/EMG signals are not obtained (step 20. d).</p>
<h3 id="sec6.12">Potential solution</h3>
<p>Replace the tether cable with a new one. During the implantation procedure, make sure that the two stoppers on the left side of the EEG are lightly touching the skull, the EMG wires are inserted into the neck extensors and are not touching each other, and that the electrode pins are clean.</p>
</section>
<section>
<h2 id="references">References</h2>
<p id="bib1">Aida, T., Yoshida, J., Nomura, M., Tanimura, A., Iino, Y., Soma, M., Bai, N., Ito, Y., Cui, W., Aizawa, H., et al. (2015). Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice. Neuropsychopharmacology <i>40</i>, 1569-1579. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref1">View at publisher</a></p>
<p id="bib13">Chen, J., Kwon, C.H., Lin, L., Li, Y., and Parada, L.F. (2009). Inducible site-specific recombination in neural stem/progenitor cells. genesis <i>47</i>, 122-131. <a class="external-link" href="https://doi.org/10.1002/dvg.20465">https://doi.org/10.1002/dvg.20465</a></p>
<p id="bib17">Diéguez-Hurtado, R., Kato, K., Giaimo, B.D., Nieminen-Kelhä, M., Arf, H., Ferrante, F., Bartkuhn, M., Zimmermann, T., Gabriele Bixel, M., Eilken, H.M., Adams, S., Borggrefe, T., Vajkoczy, P., and Adams, R.H. (2019). Loss of the transcription factor RBPJ induces disease-promoting properties in brain pericytes. Nat. Commun. <i>10</i>, 2817. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/optn6BOGt1NVN">View at publisher</a></p>
<p id="bib2">Donocoff, R.S., Teteloshvili, N., Chung, H., Shoulson, R., and Creusot, R.J. (2020). Optimization of tamoxifen-induced Cre activity and its effect on immune cell populations. Sci. Rep. <i>10</i>, 15244. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref2">View at publisher</a></p>
<p id="bib3">Funato, H., Miyoshi, C., Fujiyama, T., Kanda, T., Sato, M., Wang, Z., Ma, J., Nakane, S., Tomita, J., Ikkyu, A., et al. (2016). Forward-genetics analysis of sleep in randomly mutagenized mice. Nature <i>539</i>, 378-383. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref3">View at publisher</a></p>
<p id="bib4">Honda, T., Fujiyama, T., Miyoshi, C., Ikkyu, A., Hotta-Hirashima, N., Kanno, S., Mizuno, S., Sugiyama, F., Takahashi, S., Funato, H., et al. (2018). A single phosphorylation site of SIK3 regulates daily sleep amounts and sleep need in mice. Proc. Natl. Acad. Sci. U S A <i>115</i>, 10458-10463. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref4">View at publisher</a></p>
<p id="bib5">Huang, W.-H., Wang, D.C., Allen, W.E., Klope, M., Hu, H., Shamloo, M., and Luo, L. (2018). Early adolescent Rai1 reactivation reverses transcriptional and social interaction deficits in a mouse model of Smith-Magenis syndrome. Proc. Natl. Acad. Sci. U S A <i>115</i>, 10744-10749. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref5">View at publisher</a></p>
<p id="bib15">Huang, W., Zhao, N., Bai, X., Karram, K., Trotter, J., Goebbels, S., Scheller, A., and Kirchhoff, F. (2014). Novel NG2-CreERT2 knock-in mice demonstrate heterogeneous differentiation potential of NG2 glia during development. Glia <i>62</i>, 896-913. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/optpGnf39KtyI">View at publisher</a></p>
<p id="bib18">Ishii, S., Sasaki, T., Mohammad, S., Hwang, H., Tomy, E., Somaa, F., Ishibashi, N., Okano, H., Rakic, P., Hashimoto-Torii, K., and Torii, M. (2021). Primary cilia safeguard cortical neurons in neonatal mouse forebrain from environmental stress-induced dendritic degeneration. Proc. Natl. Acad. Sci. USA <i>118</i>. e2012482118. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/optX306FDtM1o">View at publisher</a></p>
<p id="bib6">Iwasaki, K., Fujiyama, T., Nakata, S., Park, M., Miyoshi, C., Hotta-Hirashima, N., Ikkyu, A., Kakizaki, M., Sugiyama, F., Mizuno, S., et al. (2021). Induction of mutant Sik3Sleepy allele in neurons in late infancy increases sleep need. J. Neurosci. <i>41</i>, 2733-2746. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref6">View at publisher</a></p>
<p id="bib7">Jahn, H.M., Kasakow, C.V., Helfer, A., Michely, J., Verkhratsky, A., Maurer, H.H., Scheller, A., and Kirchhoff, F. (2018). Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia. Sci. Rep. <i>8</i>, 5913. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref7">View at publisher</a></p>
<p id="bib8">Miyoshi, C., Kim, S.J., Ezaki, T., Ikkyu, A., Hotta-Hirashima, N., Kanno, S., Kakizaki, M., Yamada, M., Wakana, S., Yanagisawa, M., et al. (2019). Methodology and theoretical basis of forward genetic screening for sleep/wakefulness in mice. Proc. Natl. Acad. Sci. U S A <i>116</i>, 16062-16067. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref8">View at publisher</a></p>
<p id="bib9">Park, M., Miyoshi, C., Fujiyama, T., Kakizaki, M., Ikkyu, A., Honda, T., Choi, J., Asano, F., Mizuno, S., Takahashi, S., et al. (2020). Loss of the conserved PKA sites of SIK1 and SIK2 increases sleep need. Sci. Rep. <i>10</i>, 8676. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref9">View at publisher</a></p>
<p id="bib14">Petrik, D., Yun, S., Latchney, S.E., Kamrudin, S., LeBlanc, J.A., Bibb, J.A., and Eisch, A.J. (2013). Early Postnatal In Vivo Gliogenesis From Nestin-Lineage Progenitors Requires Cdk5. PLoS One <i>8</i>, e72819. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/optCJwxQTucGY">View at publisher</a></p>
<p id="bib10">Pitulescu, M.E., Schmidt, I., Benedito, R., and Adams, R.H. (2010). Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat. Protoc. <i>5</i>, 1518-1534. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref10">View at publisher</a></p>
<p id="bib11">Pitulescu, M.E., Schmidt, I., Giaimo, B.D., Antoine, T., Berkenfeld, F., Ferrante, F., Park, H., Ehling, M., Biljes, D., Rocha, S.F., et al. (2017). Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat. Cell. Biol. <i>19</i>, 915-927. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref11">View at publisher</a></p>
<p id="bib16">Pohlkamp, T., Steller, L., May, P., Günther, T., Schüle, R., Frotscher, M., Herz, J., and Bock, H.H. (2014). Generation and Characterization of an <i>Nse</i>-<i>CreER<sup>T2</sup></i> Transgenic Line Suitable for Inducible Gene Manipulation in Cerebellar Granule Cells. PLoS One <i>9</i>, e100384. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/optq7k29SveIx">View at publisher</a></p>
<p id="bib12">Valny, M., Honsa, P., Kirdajova, D., Kamenik, Z., and Anderova, M. (2016). Tamoxifen in the mouse brain: implications for fate-mapping studies using the tamoxifen-inducible Cre-loxP system. Front. Cell. Neurosci. <i>10</i>, 243. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00688-2/sref12">View at publisher</a></p>
</section>
<section>
<h2 id="article-info">Article info</h2>
<h3>Resource availability</h3>
<h4>Lead contact</h4>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, [Masashi Yanagisawa] (<a href="mailto:yanagisawa.masa.fu@u.tsukuba.ac.jp">yanagisawa.masa.fu@u.tsukuba.ac.jp</a>).</p>
<h4>Materials availability</h4>
<p>This study did not generate new reagents.</p>
<h4>Data and code availability</h4>
<p>This study did not generate any data, a sophisticated custom computer code, or an algorithm.</p>
<h3>Acknowledgments</h3>
<p>This work was supported by Ministry of Education, Culture, Sports, Science and Technology (World Premier International Research Center Initiative to M.Y.) and <a href="https://doi.org/10.13039/501100001691">Japan Society for the Promotion of Science</a> KAKENHI (17H06095 to M.Y. and H.F.; 16K15187, 17H04023, 17H05583, and 20H00567 to H.F.; 20J12137 to K.I.). We thank Tomoyuki Fujiyama, Aya Ikkyu, Chika Miyoshi and all Yanagisawa/Funato laboratory members and IIIS members for the kind support, technical assistance, and discussion.</p>
<h3>Author contributions</h3>
<p>Methodology, K.I. and N.H.-H.; investigation, K.I.; conceptualization, M.Y. and H.F.; writing, K.I., H.F., and M.Y.</p>
<h3>Declaration of interests</h3>
<p>The authors declare no competing interests.</p>
</section>
</article>